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Hydroxychloroquine Cardiac Toxicity in Systemic Lupus Erythematosus
Iyad N. Isseh MD, Michael P. Hudson MD, Shalini Modi MD
Division of Cardiovascular Medicine, Department of Internal Medicine, Henry Ford Hospital

Learning Objectives
• Identifying patients at risk of Hydroxychloroquine toxicity
• Diagnosing Hydroxychloroquine cardiac toxicity

Background
Prior literature details Hydroxychloroquine (HCQ) toxicities including retinopathy, neuromyopathy and cardiomyopathy. HCQ cardiac toxicity is an underdiagnosed
condition and failure to withdraw the offending drug can lead to preventable adverse effects. A strong index of suspicion is required for patients on long-term therapy with
HCQ to prevent this potentially fatal condition. We report a case of a patient with systemic lupus erythematous (SLE) found to have early HCQ cardiac toxicity.
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Conclusion
We report HCQ-induced cardiac toxicity in a patient with a high cumulative dose of HCQ diagnosed via peripheral skeletal muscle biopsy in the setting of: biphasic anterior T wave changes on ECG; mild elevation of cTnI levels; and no abnormalities on
TTE and cMR other than elevated LV mass. Our report highlights the importance of routine follow-up and screening along with a high index of suspicion in patients undergoing long-term HCQ therapy.

